Baidu
map

JACC:分期手术治疗新生儿法四患者的早期死亡风险明显更低

2019-09-22 不详 网络

对于新生儿时期就有临床表现的法洛氏四联症(TOF)患者,最佳的治疗方法尚存在争议。本研究的目的旨在比较和评估完全和分期手术对新生儿TOF患者的疗效。本研究纳入分析了国家儿童健康数据库的在出生后30天内接受完全或分期手术治疗的TOF患者,主要终点事件是术后2年随访时间内发生死亡。最终共纳入了2363名TOF患者(1032名完全手术组和1331名分期手术组),共有239名患者死亡。在2年随访时间内,完

对于新生儿时期就有临床表现的法洛氏四联症(TOF)患者,最佳的治疗方法尚存在争议。本研究的目的旨在比较和评估完全和分期手术对新生儿TOF患者的疗效。

本研究纳入分析了国家儿童健康数据库的在出生后30天内接受完全或分期手术治疗的TOF患者,主要终点事件是术后2年随访时间内发生死亡。最终共纳入了2363名TOF患者(1032名完全手术组和1331名分期手术组),共有239名患者死亡。在2年随访时间内,完全手术治疗与更高的死亡率明显相关(HR:1.51; 95% cl: 1.05-2.06)。另外,术后心脏并发症在完全手术组中也明显更多,这也导致了两组患者在术后7天和30天的死亡率差异。

研究结果显示,对于新生儿法四患者,完全手术治疗的早期和术后2年死亡风险明显高于分期手术治疗组。

原始出处:

本文系梅斯医学(MedSci)原创编译整理,转载需授权

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1854522, encodeId=fdb71854522ef, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Mon Jun 22 08:06:00 CST 2020, time=2020-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=374387, encodeId=99c13e4387c0, content=写的真好, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/21/e031c1d6c6115cbe1737b2149e602c1d.jpg, createdBy=3c105212218, createdName=147612bem32暂无昵称, createdTime=Fri Oct 25 10:30:07 CST 2019, time=2019-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1973258, encodeId=06e519e3258c7, content=<a href='/topic/show?id=7cc35939955' target=_blank style='color:#2F92EE;'>#早期死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59399, encryptionId=7cc35939955, topicName=早期死亡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bb182500058, createdName=yuhaisheng_ibp_32061711, createdTime=Fri Dec 13 23:06:00 CST 2019, time=2019-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255901, encodeId=dd1312559016e, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Tue Sep 24 01:06:00 CST 2019, time=2019-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1290716, encodeId=28e11290e168c, content=<a href='/topic/show?id=e86454454ea' target=_blank style='color:#2F92EE;'>#手术治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54454, encryptionId=e86454454ea, topicName=手术治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=920c231, createdName=lixiaol, createdTime=Tue Sep 24 01:06:00 CST 2019, time=2019-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326347, encodeId=582e132634e11, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Tue Sep 24 01:06:00 CST 2019, time=2019-09-24, status=1, ipAttribution=)]
    2020-06-22 hbwxf
  2. [GetPortalCommentsPageByObjectIdResponse(id=1854522, encodeId=fdb71854522ef, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Mon Jun 22 08:06:00 CST 2020, time=2020-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=374387, encodeId=99c13e4387c0, content=写的真好, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/21/e031c1d6c6115cbe1737b2149e602c1d.jpg, createdBy=3c105212218, createdName=147612bem32暂无昵称, createdTime=Fri Oct 25 10:30:07 CST 2019, time=2019-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1973258, encodeId=06e519e3258c7, content=<a href='/topic/show?id=7cc35939955' target=_blank style='color:#2F92EE;'>#早期死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59399, encryptionId=7cc35939955, topicName=早期死亡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bb182500058, createdName=yuhaisheng_ibp_32061711, createdTime=Fri Dec 13 23:06:00 CST 2019, time=2019-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255901, encodeId=dd1312559016e, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Tue Sep 24 01:06:00 CST 2019, time=2019-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1290716, encodeId=28e11290e168c, content=<a href='/topic/show?id=e86454454ea' target=_blank style='color:#2F92EE;'>#手术治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54454, encryptionId=e86454454ea, topicName=手术治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=920c231, createdName=lixiaol, createdTime=Tue Sep 24 01:06:00 CST 2019, time=2019-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326347, encodeId=582e132634e11, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Tue Sep 24 01:06:00 CST 2019, time=2019-09-24, status=1, ipAttribution=)]
    2019-10-25 147612bem32暂无昵称

    写的真好

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1854522, encodeId=fdb71854522ef, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Mon Jun 22 08:06:00 CST 2020, time=2020-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=374387, encodeId=99c13e4387c0, content=写的真好, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/21/e031c1d6c6115cbe1737b2149e602c1d.jpg, createdBy=3c105212218, createdName=147612bem32暂无昵称, createdTime=Fri Oct 25 10:30:07 CST 2019, time=2019-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1973258, encodeId=06e519e3258c7, content=<a href='/topic/show?id=7cc35939955' target=_blank style='color:#2F92EE;'>#早期死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59399, encryptionId=7cc35939955, topicName=早期死亡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bb182500058, createdName=yuhaisheng_ibp_32061711, createdTime=Fri Dec 13 23:06:00 CST 2019, time=2019-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255901, encodeId=dd1312559016e, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Tue Sep 24 01:06:00 CST 2019, time=2019-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1290716, encodeId=28e11290e168c, content=<a href='/topic/show?id=e86454454ea' target=_blank style='color:#2F92EE;'>#手术治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54454, encryptionId=e86454454ea, topicName=手术治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=920c231, createdName=lixiaol, createdTime=Tue Sep 24 01:06:00 CST 2019, time=2019-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326347, encodeId=582e132634e11, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Tue Sep 24 01:06:00 CST 2019, time=2019-09-24, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1854522, encodeId=fdb71854522ef, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Mon Jun 22 08:06:00 CST 2020, time=2020-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=374387, encodeId=99c13e4387c0, content=写的真好, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/21/e031c1d6c6115cbe1737b2149e602c1d.jpg, createdBy=3c105212218, createdName=147612bem32暂无昵称, createdTime=Fri Oct 25 10:30:07 CST 2019, time=2019-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1973258, encodeId=06e519e3258c7, content=<a href='/topic/show?id=7cc35939955' target=_blank style='color:#2F92EE;'>#早期死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59399, encryptionId=7cc35939955, topicName=早期死亡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bb182500058, createdName=yuhaisheng_ibp_32061711, createdTime=Fri Dec 13 23:06:00 CST 2019, time=2019-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255901, encodeId=dd1312559016e, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Tue Sep 24 01:06:00 CST 2019, time=2019-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1290716, encodeId=28e11290e168c, content=<a href='/topic/show?id=e86454454ea' target=_blank style='color:#2F92EE;'>#手术治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54454, encryptionId=e86454454ea, topicName=手术治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=920c231, createdName=lixiaol, createdTime=Tue Sep 24 01:06:00 CST 2019, time=2019-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326347, encodeId=582e132634e11, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Tue Sep 24 01:06:00 CST 2019, time=2019-09-24, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1854522, encodeId=fdb71854522ef, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Mon Jun 22 08:06:00 CST 2020, time=2020-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=374387, encodeId=99c13e4387c0, content=写的真好, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/21/e031c1d6c6115cbe1737b2149e602c1d.jpg, createdBy=3c105212218, createdName=147612bem32暂无昵称, createdTime=Fri Oct 25 10:30:07 CST 2019, time=2019-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1973258, encodeId=06e519e3258c7, content=<a href='/topic/show?id=7cc35939955' target=_blank style='color:#2F92EE;'>#早期死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59399, encryptionId=7cc35939955, topicName=早期死亡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bb182500058, createdName=yuhaisheng_ibp_32061711, createdTime=Fri Dec 13 23:06:00 CST 2019, time=2019-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255901, encodeId=dd1312559016e, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Tue Sep 24 01:06:00 CST 2019, time=2019-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1290716, encodeId=28e11290e168c, content=<a href='/topic/show?id=e86454454ea' target=_blank style='color:#2F92EE;'>#手术治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54454, encryptionId=e86454454ea, topicName=手术治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=920c231, createdName=lixiaol, createdTime=Tue Sep 24 01:06:00 CST 2019, time=2019-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326347, encodeId=582e132634e11, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Tue Sep 24 01:06:00 CST 2019, time=2019-09-24, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1854522, encodeId=fdb71854522ef, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Mon Jun 22 08:06:00 CST 2020, time=2020-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=374387, encodeId=99c13e4387c0, content=写的真好, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/21/e031c1d6c6115cbe1737b2149e602c1d.jpg, createdBy=3c105212218, createdName=147612bem32暂无昵称, createdTime=Fri Oct 25 10:30:07 CST 2019, time=2019-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1973258, encodeId=06e519e3258c7, content=<a href='/topic/show?id=7cc35939955' target=_blank style='color:#2F92EE;'>#早期死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59399, encryptionId=7cc35939955, topicName=早期死亡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bb182500058, createdName=yuhaisheng_ibp_32061711, createdTime=Fri Dec 13 23:06:00 CST 2019, time=2019-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255901, encodeId=dd1312559016e, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Tue Sep 24 01:06:00 CST 2019, time=2019-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1290716, encodeId=28e11290e168c, content=<a href='/topic/show?id=e86454454ea' target=_blank style='color:#2F92EE;'>#手术治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54454, encryptionId=e86454454ea, topicName=手术治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=920c231, createdName=lixiaol, createdTime=Tue Sep 24 01:06:00 CST 2019, time=2019-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326347, encodeId=582e132634e11, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Tue Sep 24 01:06:00 CST 2019, time=2019-09-24, status=1, ipAttribution=)]

相关资讯

JACC:非ST段抬高心梗患者院内血运重建率与出院后死亡率的相关性研究

非ST段抬高急性冠状动脉综合征(NSTE-ACS)患者院内冠状动脉血运重建率(CRR)与出院后死亡率的关系尚不清楚。本研究的目的旨在评估NSTE-ACS患者的CRR与出院后2年死亡率(2YMR)的相关性。本研究纳入分析了EPICOR临床试验中的11931名NSTE-ACS患者,基线水平患者在临床特征、药物治疗、CRR和2YMR存在明显差异,平均CRR范围为0.0% -96.8%,从罗马尼亚的12.

砥砺前行三十载,铸造学术“心长城”|第三十届长城心脏病学会议邀您参会!

第三十届长城心脏病学会议将于2019年10月10日-13日在北京国家会议中心隆重召开!届时,来自国内外的心血管及其相关领域顶级专家将汇聚一堂,群贤毕至,盛况空前。弹指间,长城心脏病学会议已走过三十年峥嵘岁月。三十载栉风沐雨,三十载砥砺前行,三十载春华秋实。长城会三十年不平凡而光辉的历程,见证了中国心血管事业的蓬勃发展。长城心脏病学会议三十年的发展历程是一幅波澜壮阔的奋斗画卷,是一首荡气回肠的壮丽史

JACC:经导管主动脉瓣置换术更适合低外科风险患者

经导管主动脉瓣置换术(TAVR)是外科主动脉瓣置换术(SAVR)中高风险患者的一个良好的选择,然而,对于低风险患者,SAVR依旧是标准的治疗方法。本次荟萃分析的目的旨在比较和评估TAVR和SAVR在低风险患者的应用。本次荟萃分析纳入分析了4个随机临床对照试验中的2887名患者(1497名TAVR组和1390名SAVR组),患者的平均年龄为75.4岁,STS-PROM平均评分为2.3%。与SAVR相

JACC:心血管循环生物标志物存在明显性别差异

男女在蛋白质组学上的差异可能导致心血管疾病生物学信号存在性别差异。本研究的目的旨在探究心血管疾病发展过程中循环生物标志物的性别差异。本研究对7184名参与者(女性占54%,平均年龄49岁)进行了71种心血管生物标志物蛋白的检测。在71种生物标志物中,有61种存在性别差异,其中37种在女性中更高,24种在男性中更高。这种性别差异在绝经前期女性与男性中最明显,在绝经后没有接受激素治疗的女性中差异明显减

JACC:口服氟喹诺酮药物会增加主动脉和二尖瓣反流风险

近期有研究认为氟喹诺酮类药物(FQs)与心脏不良事件的发生相关,包括主动脉夹层和动脉瘤。截止目前,FQs是否会增加主动脉或二尖瓣反流风险尚不清楚。本研究的目的旨在评估FQs是否会增加主动脉或二尖瓣反流风险。本研究纳入了美国IQVIA数据库中的12505名患者和125020名对照,与阿莫西林和阿奇霉素的使用者相比,FQs使用者发生主动脉或二尖瓣反流风险的比值比(RR)为 2.40 (95% CI:

JACC:低密度脂蛋白胆固醇可预测外周动脉疾病风险

低密度脂蛋白胆固醇(LDL-C)与冠心病的发生风险相关,但其与外周血管疾病的相关性尚不清楚。本研究的目的旨在评估LDL-C水平是否与视网膜病变、神经病变、慢性肾脏疾病(CKD)和外周动脉疾病(PAD)相关。 研究发现,高水平的LDL-C与视网膜病变和神经病变无明显相关性,而CKD和PAD与LDL-C水平呈逐步相关性(p<<0.001)。LDL-C每升高1mmol/L,视网膜病变的

Baidu
map
Baidu
map
Baidu
map